Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatitis C | 32 | 2024 | 1584 | 7.800 |
Why?
|
Antiviral Agents | 39 | 2024 | 3060 | 6.100 |
Why?
|
Hepacivirus | 31 | 2023 | 1336 | 5.490 |
Why?
|
Hepatitis C, Chronic | 18 | 2023 | 1032 | 4.930 |
Why?
|
Cost-Benefit Analysis | 47 | 2024 | 5492 | 4.240 |
Why?
|
Carcinoma, Hepatocellular | 11 | 2023 | 2297 | 2.420 |
Why?
|
Quality-Adjusted Life Years | 25 | 2022 | 1722 | 2.150 |
Why?
|
Liver Diseases, Alcoholic | 3 | 2023 | 156 | 2.040 |
Why?
|
Liver Neoplasms | 11 | 2023 | 4319 | 1.920 |
Why?
|
Models, Economic | 8 | 2021 | 716 | 1.880 |
Why?
|
Markov Chains | 14 | 2021 | 966 | 1.830 |
Why?
|
Liver Transplantation | 7 | 2019 | 2330 | 1.650 |
Why?
|
Models, Theoretical | 14 | 2019 | 3575 | 1.540 |
Why?
|
Anus Neoplasms | 5 | 2024 | 329 | 1.190 |
Why?
|
Prisoners | 4 | 2019 | 314 | 1.090 |
Why?
|
Health Care Costs | 8 | 2023 | 3242 | 1.040 |
Why?
|
Mass Screening | 11 | 2024 | 5428 | 0.960 |
Why?
|
Opioid-Related Disorders | 4 | 2023 | 2164 | 0.890 |
Why?
|
End Stage Liver Disease | 2 | 2019 | 352 | 0.880 |
Why?
|
Decision Support Techniques | 6 | 2021 | 1998 | 0.820 |
Why?
|
Cost of Illness | 8 | 2024 | 1936 | 0.740 |
Why?
|
Alcohol-Related Disorders | 1 | 2023 | 238 | 0.720 |
Why?
|
Epidemics | 2 | 2023 | 512 | 0.690 |
Why?
|
Disease Transmission, Infectious | 2 | 2015 | 560 | 0.680 |
Why?
|
Papillomavirus Infections | 7 | 2021 | 1613 | 0.650 |
Why?
|
Papillomavirus Vaccines | 4 | 2019 | 496 | 0.650 |
Why?
|
Liver Cirrhosis | 8 | 2023 | 1935 | 0.630 |
Why?
|
Genotype | 9 | 2019 | 12990 | 0.620 |
Why?
|
Costs and Cost Analysis | 5 | 2017 | 1668 | 0.610 |
Why?
|
Humans | 123 | 2024 | 761572 | 0.600 |
Why?
|
Online Systems | 1 | 2018 | 182 | 0.590 |
Why?
|
Pandemics | 9 | 2024 | 8656 | 0.570 |
Why?
|
Proline | 3 | 2013 | 457 | 0.570 |
Why?
|
Hepatitis, Alcoholic | 1 | 2019 | 109 | 0.570 |
Why?
|
Chenodeoxycholic Acid | 1 | 2017 | 34 | 0.560 |
Why?
|
United States | 39 | 2024 | 72335 | 0.550 |
Why?
|
Analgesics, Opioid | 4 | 2023 | 3808 | 0.530 |
Why?
|
Chemoprevention | 1 | 2018 | 326 | 0.520 |
Why?
|
Feasibility Studies | 3 | 2024 | 5247 | 0.520 |
Why?
|
Cholangitis | 1 | 2017 | 111 | 0.520 |
Why?
|
Homosexuality, Male | 4 | 2024 | 1334 | 0.510 |
Why?
|
Waiting Lists | 2 | 2019 | 765 | 0.510 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2017 | 1640 | 0.500 |
Why?
|
Drugs, Generic | 2 | 2018 | 448 | 0.500 |
Why?
|
Liver Diseases | 2 | 2023 | 1298 | 0.480 |
Why?
|
Uridine Monophosphate | 1 | 2015 | 68 | 0.480 |
Why?
|
Carcinoma in Situ | 2 | 2017 | 791 | 0.470 |
Why?
|
Fluorenes | 1 | 2015 | 157 | 0.450 |
Why?
|
Hematologic Neoplasms | 2 | 2015 | 1896 | 0.430 |
Why?
|
Prevalence | 11 | 2024 | 15732 | 0.410 |
Why?
|
Cost Savings | 2 | 2020 | 913 | 0.400 |
Why?
|
Decision Making | 5 | 2018 | 3929 | 0.400 |
Why?
|
Mass Vaccination | 1 | 2013 | 109 | 0.400 |
Why?
|
Probability | 2 | 2022 | 2477 | 0.400 |
Why?
|
Uncertainty | 1 | 2016 | 754 | 0.380 |
Why?
|
Economics, Medical | 2 | 2022 | 112 | 0.370 |
Why?
|
Gastroenterology | 1 | 2017 | 577 | 0.370 |
Why?
|
Prisons | 4 | 2023 | 174 | 0.360 |
Why?
|
Drug Costs | 2 | 2018 | 1183 | 0.360 |
Why?
|
Precancerous Conditions | 1 | 2017 | 980 | 0.360 |
Why?
|
Models, Biological | 2 | 2019 | 9469 | 0.360 |
Why?
|
Hepatitis B | 3 | 2020 | 705 | 0.350 |
Why?
|
Forecasting | 4 | 2024 | 2928 | 0.350 |
Why?
|
Risk Assessment | 11 | 2020 | 23996 | 0.350 |
Why?
|
Benzimidazoles | 1 | 2015 | 858 | 0.340 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2013 | 445 | 0.330 |
Why?
|
Schools | 2 | 2020 | 1489 | 0.330 |
Why?
|
Public Health | 5 | 2023 | 2669 | 0.320 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 1200 | 0.320 |
Why?
|
Patient Acceptance of Health Care | 2 | 2020 | 3205 | 0.310 |
Why?
|
Health Policy | 3 | 2018 | 2684 | 0.310 |
Why?
|
Spain | 2 | 2019 | 487 | 0.300 |
Why?
|
Viremia | 3 | 2023 | 707 | 0.300 |
Why?
|
Budgets | 3 | 2019 | 230 | 0.290 |
Why?
|
Middle Aged | 39 | 2024 | 220920 | 0.290 |
Why?
|
Adult | 36 | 2024 | 221203 | 0.290 |
Why?
|
Uterine Cervical Neoplasms | 4 | 2024 | 2020 | 0.280 |
Why?
|
Incidence | 10 | 2024 | 21355 | 0.280 |
Why?
|
Atrial Fibrillation | 2 | 2022 | 5127 | 0.270 |
Why?
|
Data Interpretation, Statistical | 1 | 2016 | 2691 | 0.270 |
Why?
|
Life Expectancy | 3 | 2019 | 1242 | 0.260 |
Why?
|
Female | 46 | 2024 | 392686 | 0.260 |
Why?
|
alpha-Fetoproteins | 2 | 2023 | 223 | 0.250 |
Why?
|
Male | 38 | 2024 | 360842 | 0.250 |
Why?
|
Hematologic Tests | 2 | 2023 | 239 | 0.250 |
Why?
|
Models, Statistical | 6 | 2024 | 5079 | 0.240 |
Why?
|
Treatment Outcome | 14 | 2021 | 64684 | 0.230 |
Why?
|
Moldova | 1 | 2023 | 14 | 0.230 |
Why?
|
HIV Infections | 6 | 2024 | 17352 | 0.230 |
Why?
|
Stroke | 2 | 2022 | 9758 | 0.210 |
Why?
|
Mammography | 6 | 2014 | 2430 | 0.210 |
Why?
|
Glucagon-Like Peptides | 1 | 2024 | 153 | 0.210 |
Why?
|
Basic Reproduction Number | 1 | 2022 | 36 | 0.200 |
Why?
|
Gastroplasty | 1 | 2024 | 157 | 0.200 |
Why?
|
Influenza, Human | 1 | 2013 | 1521 | 0.200 |
Why?
|
Georgia (Republic) | 1 | 2021 | 39 | 0.200 |
Why?
|
Alcohol Drinking | 3 | 2022 | 4028 | 0.200 |
Why?
|
Computer Simulation | 5 | 2020 | 6241 | 0.190 |
Why?
|
Aged | 25 | 2024 | 169310 | 0.190 |
Why?
|
Rwanda | 1 | 2024 | 665 | 0.190 |
Why?
|
Substance Abuse, Intravenous | 2 | 2023 | 529 | 0.180 |
Why?
|
Microbiological Techniques | 1 | 2021 | 97 | 0.180 |
Why?
|
Reproducibility of Results | 4 | 2020 | 20099 | 0.180 |
Why?
|
Naloxone | 1 | 2023 | 370 | 0.180 |
Why?
|
Adenosine Monophosphate | 1 | 2022 | 231 | 0.180 |
Why?
|
Brugada Syndrome | 1 | 2021 | 93 | 0.180 |
Why?
|
Economics, Pharmaceutical | 1 | 2020 | 87 | 0.170 |
Why?
|
Logistic Models | 4 | 2014 | 13255 | 0.160 |
Why?
|
Indians, North American | 1 | 2023 | 352 | 0.160 |
Why?
|
Disease Progression | 4 | 2017 | 13510 | 0.160 |
Why?
|
Alanine | 1 | 2022 | 609 | 0.160 |
Why?
|
Sentinel Surveillance | 1 | 2021 | 291 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2017 | 9280 | 0.160 |
Why?
|
Hyperthyroidism | 1 | 2021 | 294 | 0.160 |
Why?
|
Administration, Oral | 2 | 2017 | 4021 | 0.160 |
Why?
|
Pennsylvania | 3 | 2016 | 613 | 0.160 |
Why?
|
Systems Analysis | 1 | 2019 | 169 | 0.160 |
Why?
|
Tissue Donors | 2 | 2018 | 2332 | 0.150 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 218 | 0.150 |
Why?
|
Contact Tracing | 1 | 2020 | 271 | 0.150 |
Why?
|
Quarantine | 1 | 2020 | 181 | 0.150 |
Why?
|
Pakistan | 1 | 2019 | 293 | 0.150 |
Why?
|
Electric Countershock | 1 | 2021 | 533 | 0.150 |
Why?
|
Papillomaviridae | 3 | 2021 | 1119 | 0.150 |
Why?
|
France | 1 | 2019 | 497 | 0.150 |
Why?
|
Population Surveillance | 2 | 2020 | 2598 | 0.150 |
Why?
|
Bariatric Surgery | 2 | 2019 | 992 | 0.150 |
Why?
|
Comparative Effectiveness Research | 2 | 2021 | 709 | 0.150 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5440 | 0.140 |
Why?
|
Operations Research | 1 | 2017 | 22 | 0.140 |
Why?
|
Genital Diseases, Male | 1 | 2017 | 83 | 0.140 |
Why?
|
India | 3 | 2021 | 2348 | 0.140 |
Why?
|
Cohort Studies | 6 | 2018 | 41493 | 0.140 |
Why?
|
Italy | 1 | 2019 | 842 | 0.140 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39107 | 0.140 |
Why?
|
Germany | 1 | 2019 | 875 | 0.140 |
Why?
|
Policy | 1 | 2020 | 508 | 0.140 |
Why?
|
Carbamates | 1 | 2018 | 191 | 0.140 |
Why?
|
Ethanol | 1 | 2023 | 1324 | 0.140 |
Why?
|
Pharyngeal Diseases | 1 | 2017 | 134 | 0.130 |
Why?
|
Transportation of Patients | 2 | 2015 | 174 | 0.130 |
Why?
|
Genital Diseases, Female | 1 | 2017 | 192 | 0.130 |
Why?
|
Dengue | 1 | 2019 | 254 | 0.130 |
Why?
|
Vaccination | 2 | 2019 | 3384 | 0.130 |
Why?
|
Medicaid | 3 | 2019 | 2818 | 0.130 |
Why?
|
Health Priorities | 1 | 2019 | 374 | 0.130 |
Why?
|
Diagnostic Tests, Routine | 1 | 2022 | 787 | 0.130 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2021 | 464 | 0.130 |
Why?
|
Obesity, Morbid | 2 | 2017 | 1277 | 0.130 |
Why?
|
Interferon-alpha | 3 | 2015 | 921 | 0.130 |
Why?
|
Aged, 80 and over | 10 | 2020 | 58986 | 0.130 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2015 | 64 | 0.130 |
Why?
|
Postoperative Complications | 1 | 2018 | 15633 | 0.130 |
Why?
|
Japan | 1 | 2020 | 1378 | 0.130 |
Why?
|
Breast Neoplasms | 7 | 2019 | 21017 | 0.120 |
Why?
|
Fibrosis | 1 | 2022 | 2049 | 0.120 |
Why?
|
Mouth Diseases | 1 | 2017 | 241 | 0.120 |
Why?
|
World Health Organization | 2 | 2018 | 1322 | 0.120 |
Why?
|
Regional Health Planning | 1 | 2015 | 96 | 0.120 |
Why?
|
Thyroidectomy | 1 | 2021 | 908 | 0.120 |
Why?
|
Time | 1 | 2017 | 546 | 0.120 |
Why?
|
Elasticity Imaging Techniques | 1 | 2020 | 392 | 0.120 |
Why?
|
Decision Making, Computer-Assisted | 2 | 2012 | 146 | 0.120 |
Why?
|
Communicable Disease Control | 1 | 2021 | 846 | 0.120 |
Why?
|
Young Adult | 6 | 2024 | 59255 | 0.120 |
Why?
|
Nutrition Surveys | 2 | 2019 | 1733 | 0.120 |
Why?
|
Time Factors | 8 | 2021 | 39970 | 0.110 |
Why?
|
Gadolinium DTPA | 3 | 2023 | 823 | 0.110 |
Why?
|
Sensitivity and Specificity | 8 | 2023 | 14666 | 0.110 |
Why?
|
Guideline Adherence | 2 | 2021 | 2220 | 0.110 |
Why?
|
Thyroid Nodule | 1 | 2021 | 764 | 0.110 |
Why?
|
Alcoholism | 1 | 2023 | 1973 | 0.100 |
Why?
|
Suicide | 1 | 2023 | 1601 | 0.100 |
Why?
|
Linear Models | 1 | 2022 | 5872 | 0.100 |
Why?
|
RNA | 1 | 2022 | 2726 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2020 | 10212 | 0.100 |
Why?
|
Risk Factors | 12 | 2024 | 74213 | 0.100 |
Why?
|
Folic Acid | 1 | 2019 | 1323 | 0.100 |
Why?
|
Defibrillators, Implantable | 1 | 2021 | 1490 | 0.100 |
Why?
|
Biopsy, Needle | 1 | 2017 | 1626 | 0.100 |
Why?
|
Severity of Illness Index | 3 | 2019 | 15843 | 0.100 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2015 | 385 | 0.100 |
Why?
|
Hospital Costs | 1 | 2017 | 947 | 0.090 |
Why?
|
Communicable Diseases | 1 | 2019 | 875 | 0.090 |
Why?
|
Quality of Life | 5 | 2024 | 13367 | 0.090 |
Why?
|
Health Expenditures | 1 | 2023 | 2366 | 0.090 |
Why?
|
Immunization Programs | 1 | 2013 | 268 | 0.090 |
Why?
|
Neoplasms, Second Primary | 1 | 2018 | 1052 | 0.090 |
Why?
|
Early Detection of Cancer | 3 | 2024 | 3201 | 0.090 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 7827 | 0.090 |
Why?
|
Hemorrhage | 1 | 2022 | 3424 | 0.090 |
Why?
|
HIV | 1 | 2017 | 1582 | 0.090 |
Why?
|
Occupational Exposure | 1 | 2020 | 1813 | 0.090 |
Why?
|
Mental Health | 2 | 2023 | 3250 | 0.090 |
Why?
|
Trauma Centers | 1 | 2015 | 937 | 0.080 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 4853 | 0.080 |
Why?
|
Triage | 1 | 2015 | 986 | 0.080 |
Why?
|
Gastric Bypass | 1 | 2017 | 818 | 0.080 |
Why?
|
Preoperative Care | 1 | 2017 | 2242 | 0.070 |
Why?
|
Disease Management | 1 | 2018 | 2508 | 0.070 |
Why?
|
Thyroid Neoplasms | 1 | 2021 | 2332 | 0.070 |
Why?
|
Retrospective Studies | 9 | 2023 | 80646 | 0.070 |
Why?
|
Acute Disease | 1 | 2018 | 7237 | 0.070 |
Why?
|
Prospective Studies | 4 | 2021 | 54426 | 0.070 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 926 | 0.070 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1085 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3335 | 0.070 |
Why?
|
Anti-Retroviral Agents | 1 | 2016 | 1784 | 0.070 |
Why?
|
SEER Program | 3 | 2018 | 1450 | 0.070 |
Why?
|
Survival Analysis | 1 | 2019 | 10090 | 0.070 |
Why?
|
Age Factors | 2 | 2020 | 18398 | 0.060 |
Why?
|
Dietary Supplements | 1 | 2019 | 3415 | 0.060 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 1405 | 0.060 |
Why?
|
Primary Health Care | 2 | 2021 | 4686 | 0.060 |
Why?
|
Life Style | 1 | 2017 | 3917 | 0.060 |
Why?
|
Medicare | 2 | 2022 | 6770 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10766 | 0.060 |
Why?
|
ROC Curve | 2 | 2009 | 3579 | 0.060 |
Why?
|
Regression Analysis | 2 | 2014 | 6344 | 0.060 |
Why?
|
Liver | 1 | 2020 | 7529 | 0.060 |
Why?
|
Contrast Media | 3 | 2023 | 5311 | 0.060 |
Why?
|
Washington | 2 | 2015 | 315 | 0.060 |
Why?
|
Weight Loss | 3 | 2024 | 2684 | 0.060 |
Why?
|
Registries | 4 | 2018 | 8224 | 0.060 |
Why?
|
Breast | 1 | 2012 | 1967 | 0.060 |
Why?
|
Graft Rejection | 1 | 2017 | 4446 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7391 | 0.050 |
Why?
|
Adolescent | 7 | 2018 | 88324 | 0.050 |
Why?
|
Pattern Recognition, Automated | 1 | 2009 | 997 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2019 | 3763 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11076 | 0.050 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2023 | 3769 | 0.050 |
Why?
|
Calibration | 2 | 2019 | 818 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
Chronic Disease | 1 | 2018 | 9319 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2009 | 1222 | 0.050 |
Why?
|
Critical Illness | 1 | 2015 | 2723 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2015 | 3600 | 0.050 |
Why?
|
Seroepidemiologic Studies | 1 | 2023 | 397 | 0.050 |
Why?
|
Malaysia | 1 | 2021 | 107 | 0.050 |
Why?
|
Prognosis | 2 | 2020 | 29629 | 0.050 |
Why?
|
Ribavirin | 2 | 2013 | 395 | 0.050 |
Why?
|
Software | 1 | 2015 | 4434 | 0.050 |
Why?
|
Organizations, Nonprofit | 1 | 2021 | 105 | 0.050 |
Why?
|
Societies | 1 | 2021 | 108 | 0.050 |
Why?
|
Algorithms | 3 | 2017 | 14032 | 0.050 |
Why?
|
North America | 1 | 2024 | 1276 | 0.050 |
Why?
|
HIV-1 | 1 | 2017 | 6863 | 0.040 |
Why?
|
Ohio | 1 | 2020 | 322 | 0.040 |
Why?
|
Sexually Transmitted Diseases, Viral | 1 | 2019 | 40 | 0.040 |
Why?
|
Albumins | 1 | 2022 | 575 | 0.040 |
Why?
|
Bayes Theorem | 2 | 2022 | 2330 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2017 | 5336 | 0.040 |
Why?
|
Canada | 1 | 2024 | 2122 | 0.040 |
Why?
|
Human papillomavirus 18 | 1 | 2019 | 125 | 0.040 |
Why?
|
Georgia | 1 | 2018 | 185 | 0.040 |
Why?
|
Asymptomatic Diseases | 1 | 2021 | 588 | 0.040 |
Why?
|
New York | 1 | 2020 | 874 | 0.040 |
Why?
|
Vaginal Neoplasms | 1 | 2018 | 104 | 0.040 |
Why?
|
Human papillomavirus 16 | 1 | 2019 | 267 | 0.040 |
Why?
|
Criminal Law | 1 | 2018 | 97 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 36429 | 0.040 |
Why?
|
Polyethylene Glycols | 2 | 2013 | 1189 | 0.040 |
Why?
|
Poisson Distribution | 1 | 2018 | 504 | 0.040 |
Why?
|
Penile Neoplasms | 1 | 2018 | 161 | 0.030 |
Why?
|
Homosexuality | 1 | 2017 | 267 | 0.030 |
Why?
|
Vitamin B Complex | 1 | 2019 | 299 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 26127 | 0.030 |
Why?
|
Risk | 2 | 2020 | 9610 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2009 | 4063 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2020 | 495 | 0.030 |
Why?
|
National Institute on Alcohol Abuse and Alcoholism (U.S.) | 1 | 2015 | 10 | 0.030 |
Why?
|
Universities | 1 | 2021 | 993 | 0.030 |
Why?
|
Vulvar Neoplasms | 1 | 2018 | 263 | 0.030 |
Why?
|
Intracranial Hemorrhages | 1 | 2021 | 822 | 0.030 |
Why?
|
Bed Occupancy | 1 | 2015 | 38 | 0.030 |
Why?
|
Homocysteine | 1 | 2019 | 638 | 0.030 |
Why?
|
Football | 1 | 2021 | 503 | 0.030 |
Why?
|
Body Mass Index | 3 | 2017 | 12954 | 0.030 |
Why?
|
Social Class | 1 | 2022 | 2004 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3123 | 0.030 |
Why?
|
Suicidal Ideation | 1 | 2023 | 1447 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 2013 | 6534 | 0.030 |
Why?
|
Portugal | 1 | 2013 | 91 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15501 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1386 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2013 | 6312 | 0.030 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2018 | 491 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2017 | 491 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15266 | 0.030 |
Why?
|
Health Status Disparities | 1 | 2024 | 1852 | 0.030 |
Why?
|
Sex Distribution | 1 | 2017 | 2281 | 0.030 |
Why?
|
Drug Combinations | 1 | 2018 | 2048 | 0.020 |
Why?
|
Computational Biology | 1 | 2024 | 3517 | 0.020 |
Why?
|
Patient Care Team | 1 | 2023 | 2521 | 0.020 |
Why?
|
Income | 1 | 2020 | 1877 | 0.020 |
Why?
|
Recovery of Function | 1 | 2021 | 2979 | 0.020 |
Why?
|
Reoperation | 1 | 2021 | 4303 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2019 | 1372 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2578 | 0.020 |
Why?
|
Obesity | 2 | 2024 | 12947 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3358 | 0.020 |
Why?
|
Insurance, Health | 1 | 2021 | 2498 | 0.020 |
Why?
|
Electrocardiography | 1 | 2021 | 6377 | 0.020 |
Why?
|
Developing Countries | 1 | 2020 | 2885 | 0.020 |
Why?
|
Survivors | 1 | 2018 | 2371 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2017 | 2180 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8830 | 0.020 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2010 | 710 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2017 | 2791 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12725 | 0.010 |
Why?
|
Mortality | 1 | 2015 | 2901 | 0.010 |
Why?
|
Depression | 1 | 2023 | 8124 | 0.010 |
Why?
|
Patient Discharge | 1 | 2015 | 3443 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 2014 | 1923 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11121 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6766 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14607 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2013 | 12341 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2009 | 12975 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2010 | 9002 | 0.010 |
Why?
|